The promise of second-generation PI3K inhibitors for CLL - 101793

Spotlight
Video

The promise of second-generation PI3K inhibitors for CLL

VJHemOnc has 1040 videos Subscribe Here

Loading........
Description: At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.
Shared By : VJHemOnc
Posted on : 02/12/16
Added : 2 years ago